Protavio is proud to announce its official certification as service provider for the newly launched Olink Reveal platform from Olink Proteomics. This certification marks another significant milestone in our relentless pursuit of excellence in proteomic research and clinical diagnostics.
Through a rigorous certification process, Protavio successfully completed the comprehensive Olink Concordance Test for Reveal analysis, benchmarking its data quality against Olink’s Analysis Service (AS) lab in Uppsala. This outstanding performance in key metrics, including coefficient of variance (CV), detectability and correlation, underscores Protavio’s robust technical capabilities and its unwavering commitment to superior standards.
The Olink Reveal platform represents a significant advance in multiplex high-throughput proteomics, by combining Olink’s established Proximity Extension Assay (PEA) technology with next-generation sequencing (NGS) readouts. This innovative platform builds on the concepts behind the Olink Explore system but offers a new, focused assay library that enables researchers to measure over 1,000 proteins from just 4 µL of sample. The carefully curated Olink Reveal assay library provides broad pathway coverage by capturing 100% of the top biological pathways defined by Reactome, along with comprehensive immune response coverage through 537 inflammatory markers that span 96% of immune-related pathways. Additionally, the library includes over 700 proteins with documented cis-pQTLs, offering valuable insights into the genetic basis of disease, and it incorporates disease associations backed by data from the UK Biobank proteomics project. Olink Reveal’s cost-effective setup allows for the simultaneous analysis of 86 samples in a single run, making it an ideal tool for large cohort studies aimed at uncovering disease signatures and understanding inflammation mechanisms.
By integrating Olink Reveal into its offerings, Protavio, already a certified service provider for Olink Explore, further strengthens its specialized expertise in multiplex proteomics and reinforces its comprehensive Discovery, Development, and Manufacturing (DDM) pipeline. Leveraging Olink’s state-of-the-art technology alongside Protavio’s advanced In Vitro Diagnostic (IVD) development processes and stringent Good Manufacturing Practice (GMP) standards, the company is uniquely equipped to deliver end‑to‑end solutions, from the initial stages of biomarker discovery through assay development to final clinical deployment, while ensuring seamless transitions from research to reliable diagnostic applications through strict adherence to ISO13485, IVDR, GMP, and FDA guidelines. This certification not only solidifies Protavio’s leadership in proteomics innovation but also empowers the scientific community to translate breakthrough discoveries into robust diagnostic tools that enhance patient care, drive scientific progress, and ultimately improve patient outcomes.